
Met Opera attendance dropped in spring as tourism fell, coinciding with immigration crackdown
NEW YORK — Metropolitan Opera season attendance dropped slightly following the Trump administration's immigration crackdown that coincided with a decrease in tourists to New York.
The Met sold 72% of capacity, matching 2023-24 and down from its 75% projection.
'We were on track to continue to improve,' Met general manager Peter Gelb said Friday. 'We were disappointed by the sales in the last two months of the season — our projections were much higher and I attribute the fact that we didn't achieve our sales goals to a significant drop in tourism."
New York City Tourism & Conventions last month reduced its 2025 international visitor projection by 17%, the Met said.
International buyers accounted for 11% of sales, down from the Met's projection of 16% and from about 20% before the coronavirus pandemic.
'It's unfortunate, but this is the times in which we live,' Gelb said.
The Met said factoring ticket discounts, it realized 60% of potential income, down from 64% in 2023-24 but up from 57% in 2022–23.
'We were able to sell an equal amount of tickets the last year, but there were more discounted tickets,' Gelb said. 'This really was the result of the last two months of the season.'
There were 76,000 new ticket buyers, a drop from 85,000 in 2023-24, and the average age of single ticket buyers was 44, the same as in the previous season and a drop from 50 before the pandemic. Subscriptions accounted for just 7% of ticket sales, down from 12-15% before the pandemic,
Gelb said economic uncertainty impacted sales for next season.
'The stock market jumping up and down made people feel insecure,' he said. 'In one week we saw an enormous decline in our advance for next season. Then it picked up again.'
Met music director Yannick Nézet-Séguin earned $2,045,038 in the year end last July 31, up from $1,307,583, in the previous fiscal year, according to the company's tax return released Friday. Gelb earned $1,395,216, roughly the same as his $1,379,032 in 2022-23,and he also accrued $798,205 listed as retirement or deferred compensation.
Assets declined by about $40 million to $467 million, primarily because of an endowment draw following the pandemic.
Among individual productions last season, the highest percentage of tickets sold were for the English-language version of Mozart's 'The Magic Flute' and a new staging of Verdi's 'Aida,' both at 82%, followed by the company premiere of Jake Heggie's 'Moby-Dick' at 81%
Other new productions included Strauss' 'Salome' (74%), John Adams' 'Antony and Cleopatra' (65%), Osvaldo Golijov's 'Ainadamar' (61%) and Jeanine Tesori's 'Grounded' (50%).
The best-selling revivals were Puccini's 'Tosca' (78%), Tchaikovsky's 'Pique Dame (The Queen of Spades)' and Puccini's La Bohème (77% each), Beethoven's 'Fidelio' and Rossini's 'Il Barbiere di Siviglia' (76% each) and Mozart's 'Le Nozze di Figaro' (71%).
Lagging were Strauss' 'Die Frau ohne Schatten' (68%0, Verdi's 'Rigoletto' (64%), Offenbach's 'Les Contes d'Hoffmann' and the German-language version of Mozart's 'Die Zauberflöte' (62% each) and Verdi's 'Il Trovatore' (59%).
Ronald Blum, The Associated Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
5 minutes ago
- Globe and Mail
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
Johnson & Johnson JNJ announced strong second-quarter results earlier this month. The drug and medical device giant beat estimates for both earnings and sales. Despite the loss of exclusivity ('LOE') of its blockbuster drug, Stelara, its Innovative Medicine unit once again outperformed expectations, with sales of all key drugs Darzalex, Erleada and Tremfya beating estimates. The new drugs also contributed significantly to sales. Importantly, its MedTech sales improved from first-quarter levels, driven by strong momentum in Cardiovascular, Surgery and Vision segments despite continued headwinds in China. But what caught investor attention is the fact that J&J raised its sales expectations for 2025 by around $2.0 billion at the mid-point to reflect a strong operational performance in the first half, coupled with currency tailwinds. The sales guidance was raised from a range of $91.0 billion-$91.8 billion to $93.2 billion-$93.4 billion. The sales range indicates growth in the range of 5.1%-5.6% versus the prior expectation of 2.6%-3.6%. The adjusted earnings per share guidance was raised from a range of $10.50-$10.70 to $10.80-$10.90, driven by top-line strength, the favorable impact of foreign currency and lowered tariff impact. J&J halved its expectations for tariff-related costs this year from $400 million to $200 million. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first. Newly launched products should drive better growth in the Innovative Medicine segment in the second half despite the impact of Stelara LOE and Medicare Part D redesign. The growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato and Erleada as well as new drugs like Carvykti, Tecvayli and Talvey and new indications, including Tremfya in inflammatory bowel disease indications and Rybrevant in non-small cell lung cancer. In the MedTech segment, the increased adoption of newly launched products in Cardiovascular, Surgery and Vision is likely to drive growth. However, China will continue to be a headwind in 2025. Sales are expected to be higher in the second half than the first half as the business moves past tougher first-half comps and new products gain momentum throughout 2025. We believe that J&J should be able to maintain the strong momentum of the first half in the second half. In fact, J&J expects growth to accelerate from 2026. ABBV & BMY Also Raise Guidance Other drugmakers that also raised their financial outlook for the year, along with their second-quarter results, are AbbVie ABBV and Bristol-Myers BMY. ABBV raised its full-year 2025 EPS guidance to $11.88-$12.08, up from its prior $11.67-$11.87 range.' Bristol-Myers raised its annual revenue guidance to $46.5-$47.5 billion from $45.8-$46.8 billion. BMY, however, cut its EPS outlook due to IPRD charges related to its recent deal with BioNTech BNTX for the global co-development and co-commercialization of BNTX's investigational bispecific antibody BNT327 across numerous solid tumor types. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 17.6% in the year-to-date period against a 3.3% decrease of the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company's shares currently trade at 15.0 forward earnings, slightly higher than 14.29 for the industry. The stock is, however, trading below its five-year mean of 15.68. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has risen from $10.62 per share to $10.86 over the past 30 days, while that for 2026 has risen from $11.0 to $11.36 over the same timeframe. Image Source: Zacks Investment Research J&J has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report


National Post
5 minutes ago
- National Post
WWE megastar returns at SummerSlam amidst sex trafficking lawsuit
Shocking returns are a common occurrence in the world of professional wrestling, but this one really caught fans off guard. Article content After the main event of WWE SummerSlam on Sunday night, Brock Lesnar made his return to the squared circle, coming down to the ring and putting a beatdown on John Cena. Article content Article content Lesnar, who had been away from the company for two years, had been named in the ongoing sex trafficking lawsuit against former WWE head honcho Vince McMahon. Article content BROCK. LESNAR. IS. BACK. HERE COMES THE PAIN! 👊 — WWE (@WWE) August 4, 2025 Article content In the lawsuit, which was filed in January 2024, McMahon is accused of sexual assault and sex trafficking by former WWE employe Janel Grant. Article content While Grant's original complaint did not include Lesnar's name — it only referencing a 'world-famous athlete and former UFC Heavyweight Champion' — he was officially named by Grant in federal court in an amended complaint in February. Article content In the suit, Grant accused McMahon of asking her to create 'personalized sexual content' for Lesnar — who is not a defendant in the case — during his contract negotiations and that McMahon flew the superstar to Connecticut in 2021 for a sexual encounter that didn't end up happening. Article content McMahon has denied all allegations by Grant while his attorney called naming Lesnar in the suit a 'publicity stunt.' Article content 'As expected, the proposed amended complaint is nothing more than the latest publicity stunt in an ongoing smear campaign,' McMahon's attorney Jessica Rosenberg said in a statement to ESPN. 'It is filled with desperate falsehoods from a team that continues to disregard the law and the truth.' Article content With the lawsuit ongoing, the company had made efforts to distance itself from Lesnar, taking down his merchandise from its online store and removing his playable character from the WWE 2K24 video game. Article content Article content His previous appearance had been at SummerSlam in 2023, which also was held at MetLife Stadium in East Rutherford, N.J. On Sunday night, after Cody Rhodes defeated Cena to win the WWE Universal Championship, Lesnar came down to the ring and hit his F5 finishing move on Cena before celebrating. Article content His appearance garnered a mixed reaction by those in attendance and was widely criticized on social media. Article content WWE defended its decision to bring back Lesnar despite the allegations and ongoing nature of the suit. Article content 'My reaction was exactly what I thought it was gonna be, which was, if there had been a roof on this place, it wouldn't be here anymore,' WWE chief content officer Paul 'Triple H' Levesque said during the SummerSlam post-show. Article content 'The dynamic in the room in WWE changes when The Beast is here,' he added. 'Seeing Brock Lesnar come back, anything that you thought was happening sort of all goes out the window because the factor of Brock now just changes that dynamic so incredibly. It makes it unpredictable.'


Globe and Mail
5 minutes ago
- Globe and Mail
Stock Market News for Aug 4, 2025
U.S. stocks tumbled on Friday, with the S&P 500 recording its biggest daily percentage decline in over two months, as hefty tariffs slapped on dozens of countries by President Donald Trump and an unexpectedly weak jobs report raised concerns over a weakening economy. All three major indexes ended in negative territory. How Did The Benchmarks Perform? The Dow Jones Industrial Average (DJI) slid 1,2% or 542.40 points, to finish at 43,588.58 points. The S&P 500 declined 1.6%, or 101.38 points, to end at 6,238.01 points, posting its worst day since May 21. Consumer discretionary, tech and financial stocks were the worst performers. The Consumer Discretionary Select Sector SPDR (XLY) declined 2.4%. The Financials Select Sector SPDR (XLF) and the Technology Select Sector SPDR (XLK) slid 2.2 and 1.9%, respectively. Eight of the 11 sectors of the benchmark index ended in negative territory. The tech-heavy Nasdaq fell 2.2%, or 472.32 points, to close at 20,650.13 points, recording its biggest single-day decline since April 21. The fear gauge CBOE Volatility Index (VIX) was up 21.89% to 20.38. Decliners outnumbered advancers on the NYSE by a 2.17-to-1 ratio. On the Nasdaq, a 2.69-to-1 ratio favored declining issues. A total of 19.51 billion shares were traded on Friday, higher than the last 20-session average of 18.44 billion. Trump's New Tariffs, Weak Jobs Data Dent Investors' Confidence Trump signed an executive order hours before the Aug. 1 tariff deadline and slapped hefty duties on several trading partners of the United States, including Brazil, Canada, India and Taiwan, as these countries scrambled to work out fairer trade deals. Investors grew concerned once again as they believe that hefty tariffs could weigh on an already weakening economy and push inflation further up. Investors' confidence took a further hit after fresh data showed that jobs growth unexpectedly slowed in July, while June's numbers were downwardly revised, suggesting that the labor market is likely shrinking. Bank stocks took a hit on concerns that a slowing economy could impact loan growth. Shares of JPMorgan Chase & Co. ( JPM ) fell 2.3%, while Bank of America Corporation ( BAC ) and Wells Fargo & Company ( WFC ) declined 3.4% and 3.5%, respectively. This, however, raised hopes that the Federal Reserve will cut interest rates in its September policy meeting. The weak jobs data raised market expectations of a 25-basis-point rate cut in September to 86.5%, according to the CME's FedWatch Tool, up from 37.7% in Thursday's session. Amazon Weighs on Broader Market E-commerce giant Inc. ( AMZN ) was the biggest drag on all three major indexes. Amazon topped both earnings and revenue estimates. The company reported second-quarter earnings of $1.68 per share, beating the Zacks Consensus Estimate of $1.33 per share. The e-commerce giant posted revenues of $167.7 billion for the quarter, surpassing the Zacks Consensus Estimate by 3.32% However, the company's shares declined 8.3% after it failed to meet the expectations for its Amazon Web Services. Amazon Web Services revenues grew 18% in the second quarter, but its growth rate lagged Microsoft Corporation's ( MSFT ) Azure's 39% and Alphabet, Inc.'s ( GOOGL ) Google Cloud's 32% growth rate. Amazon has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Economic Data The Labor Department reported on Friday that nonfarm payrolls increased by just 73,000 in July, sharply lower than analysts' expectations of a rise of 100,000. June's jobs growth was downwardly revised to just 14,000, from 147,000, while May's numbers totaled just 19,000 after being cut down from the initially reported 125,000. The unemployment rate jumped to 4.2% in July as household employment declined. Weekly Roundup All three indexes ended lower for the week. The Dow lost 2.9% for the week. The S&P 500 was down 2.4% for the week, while the Nasdaq lost 2.2%. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report Bank of America Corporation (BAC): Free Stock Analysis Report Wells Fargo & Company (WFC): Free Stock Analysis Report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report